MAGE-C1 Antibody (F-2): sc-377473

MAGE-C1 Antibody (F-2) is a mouse monoclonal IgG2a antibody that detects MAGE-C1 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MAGE-C1, also known as CT7, is a member of the melanoma-associated antigen (MAGE) family, which is primarily recognized for its role in tumor rejection and its expression in various tumors, particularly in multiple myeloma, where MAGE-C1 correlates with plasma-cell proliferation. The significance of MAGE-C1 lies not only in tumor-specific expression but also in potential as a target for cancer immunotherapy, as MAGE-C1 is virtually absent in normal tissues, with the exception of the testis and placenta. Understanding MAGE-C1 structure is crucial, as MAGE-C1 contains a unique domain that allows for interaction with specific proteins involved in immune response modulation, thereby influencing the efficacy of T lymphocyte recognition and activation against tumor cells. Anti-MAGE-C1 antibody (F-2) serves as a valuable tool for researchers investigating the mechanisms of tumor immunity and the development of targeted cancer therapies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MAGE-C1 Antibody (F-2) References:

1. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome.  |  Tinguely, M., et al. 2008. Cancer Sci. 99: 720-5. PMID: 18307538
2. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.  |  Atanackovic, D., et al. 2010. Haematologica. 95: 785-93. PMID: 20015885
3. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.  |  Pabst, C., et al. 2010. Exp Mol Pathol. 89: 175-81. PMID: 20621094
4. Expression of MAGE-A4 and MAGE-C1 tumor-associated antigen in benign and malignant thyroid diseases.  |  Melo, DH., et al. 2011. Head Neck. 33: 1426-32. PMID: 21246638
5. Expression of cancer-testis antigens MAGE-A4 and MAGE-C1 in oral squamous cell carcinoma.  |  Montoro, JR., et al. 2012. Head Neck. 34: 1123-8. PMID: 22083937
6. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.  |  de Carvalho, F., et al. 2013. Cancer Immunol Immunother. 62: 191-5. PMID: 23180015
7. The use of MAGE C1 and flow cytometry to determine the malignant cell type in multiple myeloma.  |  Wienand, K. and Shires, K. 2015. PLoS One. 10: e0120734. PMID: 25793710
8. Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma.  |  Curioni-Fontecedro, A., et al. 2015. Biomed Res Int. 2015: 432479. PMID: 26161400
9. Expression of MAGE-C1/CT7 provides prognostic information in multiple myeloma.  |  Xu, P., et al. 2017. Leuk Lymphoma. 58: 244-246. PMID: 27248683
10. Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases.  |  Melo, DH., et al. 2017. Oncol Lett. 14: 6485-6496. PMID: 29163685

The preferred MAGE-C1 antibody is MAGE-C1 Antibody (CT7-33): sc-53868.